Patients with Obesity Undergoing Treatment with Semaglutide or Tirzepatide
Conditions
Interventions
None listed
Sponsors
Shiga University of Medical Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with obesity who receive treatment with semaglutide or tirzepatide during the registration period and meet either of the following criteria will be included in the study: A body mass index (BMI) of 27 kg/m2 or higher; or A BMI below 30 kg/m2 accompanied by two or more obesity-related comorbidities. The obesity-related comorbidities considered for inclusion are as follows: impaired glucose tolerance, dyslipidemia, hypertension, hyperuricemia or gout, coronary artery disease, cerebral infarction or transient ischemic attack, non-alcoholic fatty liver disease (NAFLD), menstrual disorders or infertility, obstructive sleep apnea, musculoskeletal disorders, and obesity-related kidney disease.
Exclusion criteria
Exclusion criteria: Participants will be excluded from the study if they meet any of the following conditions: Pregnant or breastfeeding women; Patients with a body weight of 135 kg or more; Any other individuals deemed inappropriate for participation in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in exercise capacity before and after the initiation of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of pre- and post-treatment changes in body weight, body composition, obesity-related comorbidities, and findings from clinical tests and functional assessments | — |
Countries
Japan
Contacts
Public ContactKensuke Takabayashi
Shiga University of Medical Science Department of Cardiovascular Medicine
Outcome results
None listed